Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Beth Israel Deaconess Medical Center
Study ID
NCT00073957
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • rituximab — BIOLOGICAL
  • cytarabine — DRUG
    to be used for CNS prophylaxis
  • liposomal cytarabine — DRUG
    to be used as CNS prophylaxis
  • yttrium Y 90 ibritumomab tiuxetan — RADIATION

Study Details

RATIONALE: Monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan and rituximab, can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Combining yttrium Y 90 ibritumomab tiuxetan with rituximab may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining yttrium Y 90 Ibritumomab tiuxetan with rituximab in treating patients who have relapsed or refractory diffuse large B-cell non-Hodgkin's lymphoma.

Key Dates

Start date
Dec 31, 2003
Status verified
Dec 2017
Primary completion
Jan 1, 2012
Completion
Jan 1, 2012

Study Design

Enrollment
25 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Y-90 Ibritumomab Tiuxetan
    Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab and central nervous system prophylaxis with Cytarabine or liposomal cytarabine

Primary Outcome Measure

Response Rate = Complete and Partial Response at 12 Weeks. [ Time Frame: 12 weeks ]

Locations (2)

FacilityCityStateZIPSite coordinators
Beth Israel Deaconess Medical CenterBostonMassachusetts02215-
Fletcher Allen Health Care - Medical Center CampusBurlingtonVermont05401-

Find similar trials in Boston, MA

By research site
Beth Israel Deaconess Medical Center· Boston, MAFletcher Allen Health Care - Medical Center Campus· Burlington, VT

Related Studies